Filing Details
- Accession Number:
- 0001209191-23-058701
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-12-14 18:51:24
- Reporting Period:
- 2023-12-12
- Accepted Time:
- 2023-12-14 18:51:24
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1601830 | Recursion Pharmaceuticals Inc. | RXRX | Biological Products, (No Disgnostic Substances) (2836) | 464099738 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1856094 | Blake Borgeson | C/O Recursion Pharmaceuticals 41 S. Rio Grande Street Salt Lake City UT 84101 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Disposition | 2023-12-12 | 11,447 | $7.40 | 7,384,526 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Direct |
Footnotes
- Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.
- The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.26 to $7.51 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.